The BER pathway is widely used to repair DNA damage in cells, but it can also introduce unwanted mutations and is sometimes hijacked by other pathways.
DNA can be damaged in many ways—bases can, for example, be oxidized, alkylated or deaminated—so cells need a way to repair DNA damage. Sometimes it is possible to reverse the process that caused these ‘base lesions’, but cells tend to employ a more complex approach that is called the base excision repair (BER) pathway. This process involves three basic steps: first, enzymes called nucleases break the DNA strand that is damaged on either side of the lesion so that the section containing the lesion can be removed; second, DNA polymerases make a new stretch of DNA to replace the section that has been removed, using the undamaged strand as a template; third, DNA ligases join this new stretch to the existing DNA.
However, there is a ‘dark side’ to DNA repair because the process by which the replacement DNA is synthesized is inherently error-prone. Moreover, DNA is normally tightly packaged inside the nucleus to protect it from damage: however, the BER pathway involves regions of DNA being unpackaged, and this provides other enzymes and repair pathways with access to the DNA, which can lead to lesions and mutations. The overall result is that DNA repair can sometimes lead to more rather than less damage and, in some cases, this damage can ultimately kill the cell (Fu et al., 2012).
Large-scale DNA sequencing has revealed a complex pattern of lesions and mutations that includes mutational hotspots and mutations that are linked to specific sequences of bases. In some cases the mutations appear to be linked to enzymes belonging to the APOBEC family—which change the cytosine bases in DNA into uracil bases—being able to access the DNA (Roberts et al., 2013; Nik-Zainal et al., 2014). Finally, some seemingly random mutations occur with high frequency.
Now, in eLife, Jia Chen, Brendan Miller and Anthony Furano—who all are based at the National Institute of Diabetes and Digestive and Kidney Diseases—have used DNA sequencing to explore the accuracy of the BER pathway in mammalian cells (Chen et al., 2014). They used genetic techniques to deliberately introduce lesions associated with different sub-pathways of the BER pathway. These lesions included: a simple strand break between two neighbouring bases (which is known as a nick); replacing the cytosine base opposite a guanine base with an abasic site; and various types of base mismatches (such as thymine/guanine, uracil/guanine or hydroxymethyl-uracil/guanine instead of cytosine/guanine). The lesions were individually engineered into episomal DNA, and the episomes were allowed to undergo repair in mammalian cells and then isolated. After passage through E. coli, mutants were selected, and the DNA was subjected to sequence analysis.
As expected, most of the lesions were repaired by the BER pathway (Figure 1), but there were interesting differences in the repair of the different types of lesions. In some cases, for example, there were mutations in the template strand, rather than the strand containing the lesion, which suggests that various enzymes had been able to access the template strand during the repair process.
Moreover, mutations were observed in the bases on one side of the base lesion (distal to the lesion). These ‘flanking mutations’ were shown to depend on the initial steps of the BER pathway in most cases. A number of enzymes are known to be capable of exposing single-stranded DNA on either side of a nick, but it seems surprising that the molecular machinery responsible for the BER pathway allowed these enzymes to have access to the lesions. Previously it was thought that each enzyme in the BER pathway ‘handed over’ to the next enzyme in a highly coordinated process that left little scope for third parties to have access to the DNA (Prasad et al., 2010), but the presence of the flanking mutations suggests that the lesion recognition and hand-over process is not always able to keep third parties away from the lesion.
So what actually causes the flanking mutations? Chen, Miller and Furano suggest that the BER pathway is ‘hijacked’ by another DNA repair pathway called the mismatch repair system (which, as its name suggests, repairs base mismatches). They provided evidence for this by showing that depleting factors involved in the mismatch repair system results in a reduction in flanking mutations.
Chen et al. also noticed that many of the flanking mutations involved cytosine bases that were preceded by thymine bases, with the cytosine bases changing to uracil bases. This pattern suggested that certain APOBEC enzymes—those that have a preference for the TpC sequence in single-stranded DNA—were involved. To test this idea Chen et al. depleted the level of APOBEC enzymes and, as they predicted, there was a drop in the number of flanking mutations. Taken together, the results point to the idea that the mismatch repair machinery exposes single-stranded DNA that serves as a substrate for the APOBEC enzymes, which remove amine groups from the cytosine bases to leave uracil bases (Roberts et al., 2012, 2013). DNA synthesis to copy the single-stranded DNA then leads to mutations.
Overall, the results reported by Chen, Miller and Furano open up a whole new range of questions about the introduction of mutations during DNA repair.
Balancing repair and tolerance of DNA damage caused by alkylating agentsNature Reviews Cancer 12:104–120.https://doi.org/10.1038/nrc3185
Substrate channeling in mammalian base excision repair pathways: passing the batonJournal of Biological Chemistry 285:40479–40488.https://doi.org/10.1074/jbc.M110.155267
Downloads (link to download the article as PDF)
Download citations (links to download the citations from this article in formats compatible with various reference manager tools)
Open citations (links to open the citations from this article in various online reference manager services)
Many photosynthetic organisms employ a CO2 concentrating mechanism (CCM) to increase the rate of CO2 fixation via the Calvin cycle. CCMs catalyze ≈50% of global photosynthesis, yet it remains unclear which genes and proteins are required to produce this complex adaptation. We describe the construction of a functional CCM in a non-native host, achieved by expressing genes from an autotrophic bacterium in an Escherichia coli strain engineered to depend on rubisco carboxylation for growth. Expression of 20 CCM genes enabled E. coli to grow by fixing CO2 from ambient air into biomass, with growth in ambient air depending on the components of the CCM. Bacterial CCMs are therefore genetically compact and readily transplanted, rationalizing their presence in diverse bacteria. Reconstitution enabled genetic experiments refining our understanding of the CCM, thereby laying the groundwork for deeper study and engineering of the cell biology supporting CO2 assimilation in diverse organisms.
Since the 1960s, a single class of agent has been licensed targeting virus-encoded ion channels, or ‘viroporins’, contrasting the success of channel blocking drugs in other areas of medicine. Although resistance arose to these prototypic adamantane inhibitors of the influenza A virus (IAV) M2 proton channel, a growing number of clinically and economically important viruses are now recognised to encode essential viroporins providing potential targets for modern drug discovery. We describe the first rationally designed viroporin inhibitor with a comprehensive structure-activity relationship (SAR). This step-change in understanding not only revealed a second biological function for the p7 viroporin from hepatitis C virus (HCV) during virus entry, but also enabled the synthesis of a labelled tool compound that retained biological activity. Hence, p7 inhibitors (p7i) represent a unique class of HCV antiviral targeting both the spread and establishment of infection, as well as a precedent for future viroporin-targeted drug discovery.